Veterans Affairs Lung Cancer Or Stereotactic Radiotherapy



Status:Recruiting
Conditions:Lung Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:12/15/2018
Start Date:April 13, 2017
End Date:September 30, 2027
Contact:Drew Moghanaki, MD MPH
Email:Drew.Moghanaki@va.gov
Phone:(804) 306-9045

Use our guide to learn which trials are right for you!

CSP #2005 - Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy Trial (VALOR)

Patients with stage I non-small cell lung cancer have been historically treated with surgery
whenever they are fit for an operation. However, an alternative treatment known as
stereotactic radiotherapy now appears to offer an equally effective alternative. Doctors
believe both are good treatments and are therefore conducting this study to determine if one
may be possibly better than the other.

The standard of care for stage I non-small cell lung cancer has historically been surgical
resection in patients who are medically fit to tolerate an operation. Recent data now
suggests that stereotactic radiotherapy may be a suitable alternative. This includes the
results from a pooled analysis of two incomplete phase III studies that reported a 15%
overall survival advantage with stereotactic radiotherapy at 3 years. While these data are
promising, the median follow-up period was short, the results underpowered, and the findings
were in contradiction to multiple retrospective studies that demonstrate the outcomes with
surgery are likely equal or superior. Therefore, the herein trial aims to evaluate these two
treatments in a prospective randomized fashion with a goal to compare the overall survival
beyond 5 years. It has been designed to enroll patients who have a long life-expectancy, and
are fit enough to tolerate an anatomic pulmonary resection with intraoperative lymph node
sampling.

This study is designed to open at Veterans Affairs medical centers with expertise in both
treatments. The recruitment process includes shared decision making and multi-disciplinary
evaluations with lung cancer specialists. Mandatory evaluations before randomization include
tissue confirmation of NSCLC, staging with FDG-PET/CT, and biopsies of all hilar and/or
mediastinal lymph nodes >10mm that have a SUV >2.5. Pre-randomization elective lymph node
sampling is strongly encouraged, but not required. Following treatment, patients will be
followed for a minimum of 5 years.

Inclusion Criteria:

Inclusion Criteria for Screening

- Age 18 or older

- Any patient with a preliminary diagnosis of stage I Non-Small Cell Lung Cancer
(NSCLC), whether pathologically proven by biopsy, or highly suspicious by radiographic
imaging. [Participants will ultimately need biopsy confirmation before enrolling]

- Primary tumor size less than or equal to 5 cm by CT (may include CT images from
PET/CT)

- Karnofsky performance status greater than or equal to 70

- Participant has willingness and ability to provided informed consent for participation

Inclusion Criteria for Randomization

- Biopsy proven non-small cell lung cancer

- Participant's case reviewed at multidisciplinary conference

- Tumor size less than or equal to 5cm (measured on the most recent CT images available,
and may include PET/CT images)

- Tumor is equal to or greater than 1.0cm from the trachea, esophagus, brachial plexus,
1st bifurcation of the proximal bronchial tree, or spinal cord (measured on the most
recent CT images available, and may include PET/CT images).

- Mandatory FDG-PET/CT within 60 days of the randomization date (note: FDG-PET/CT may
need to be repeated prior to treatment if outside of this requirement)

- Mandatory pathological assessment of any lymph nodes >10mm with a SUV >2.5 seen on
FDG- PET/CT

- Mandatory biopsy of any additional concerning lesions seen on FDG-PET/CT, to make
better determination that the patient is not harboring metastatic disease or a
secondary primary malignancy.

- Pre-operative FEV1 greater than or equal to 40% of predicted value and pre-operative
DLCO greater than or equal to 40% of predicted value.

- Formally evaluated and documented by a local thoracic surgeon to be medically fit to
undergo a complete anatomic pulmonary resection (wedge resection not allowed)

- Formally evaluated and documented by a local radiation oncologist to be eligible to
receive protocol-defined stereotactic radiotherapy

- Participant willingness to be randomized

Exclusion Criteria:

Exclusion Criteria for Screening

- Previously evaluated by a local thoracic surgeon and determined to be medically
inoperable

- Pathological confirmation of nodal or distant metastasis

- Prior history of lung cancer, not including current lesion

- Prior history of thoracic surgery or lung or esophageal cancer. [prior cardiac surgery
acceptable]

- Prior history of radiotherapy to the thorax

- Prior history of an invasive malignancy within the past 5 years, whether newly
diagnosed or recurrent, excluding low-risk prostate cancer, non-melanoma skin cancers,
and in-situ cancers

- Ever diagnosed with stage IV metastatic cancer of any type

- History of scleroderma

- Positive Pregnancy test (for women <61 years of age or without prior hysterectomy)

Exclusion Criteria for Randomization

- Pathological confirmation of nodal or metastatic disease
We found this trial at
9
sites
Richmond, Virginia 23249
Phone: 804-675-5606
?
mi
from
Richmond, VA
Click here to add this to my saved trials
Bay Pines, Florida 33708
Phone: 727-398-6661
?
mi
from
Bay Pines, FL
Click here to add this to my saved trials
Durham, North Carolina 27705
?
mi
from
Durham, NC
Click here to add this to my saved trials
?
mi
from
Hines, IL
Click here to add this to my saved trials
?
mi
from
Houston, TX
Click here to add this to my saved trials
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Long Beach, California 90822
Phone: 562-826-5591
?
mi
from
Long Beach, CA
Click here to add this to my saved trials
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Pittsburgh, Pennsylvania 15240
Phone: 412-360-6316
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials